

20<sup>th</sup> December, 2023

1]  
**The Secretary**  
**The Calcutta Stock Exchange Limited**  
7, Lyons Range  
Kolkata 700 001  
Scrip code: 10023915

2]  
**Listing Department**  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (E), Mumbai - 400 051  
Scrip code: MAITHANALL

**Sub: Acquisition**

Dear Sir/Madam,

We enclose herewith the details required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III of the said Regulations and SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 in respect of acquisition of equity shares of listed company through Stock Exchange.

The event has occurred on 31<sup>st</sup> August, 2023 at 3:30 P.M.

This is for your information and records.

Thanking you,

Yours faithfully,

**For Maithan Alloys Limited**

Rajesh K. Shah  
**Company Secretary**

cc: The Corporate Relationship Department  
**BSE Limited**  
Rotunda Building, P.J. Towers  
Dalal Street, Fort, Mumbai- 400 001  
Scrip Code: 590078

Name of the target entity	NATCO PHARMA LTD.
<b>Details in brief such as size, turnover etc.</b>	<b>AS AT 31.03.2023</b>
Turnover	Rs. 2351 Crore
PAT	Rs. 637 Crore
Networth	Rs. 4702 Crore
Whether the acquisition would fall within Related Party Transaction(s)?	No
Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?	No
If yes, Nature of interest and details thereof	Not Applicable
Whether the same is done at "arms length"?	Yes
Industry to which the entity being acquired belongs	Pharmaceuticals
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The shares were acquired through stock exchange and form part of current investment of the Maithan Alloys Ltd. with view to reap the long-term/short-term investment benefits.  <b>The Maithan Alloys Limited do not intend to acquire control of either management or of the Target entity.</b>
Brief details of any governmental or regulatory approvals required for the acquisition	No
Indicative time period for completion of the acquisition	Event has occurred on 31 <sup>st</sup> August, 2023 and acquisition is completed.
Nature of consideration- whether cash consideration or share swap or any other form and details of the same	Cash Consideration
Cost of acquisition or the price at which the shares are acquired (Total value) ( Rs in Crore)	Cost of acquisition Rs. 11.89 Crore on 31 <sup>st</sup> August, 2023
Percentage of shareholding / control acquired and / or number of shares acquired;	0.0728% of shareholding (being 130440 shares) were acquired on 31 <sup>st</sup> August, 2023 Total 0.2609% of shareholding (being 467340 shares) were acquired till 31 <sup>st</sup> August, 2023
Brief background about the entity acquired in terms of products/line of business acquired	NATCO Pharma Limited is a public limited company domiciled and incorporated in with its registered office situated at Hyderabad (Telangana). The Company is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations.
Date of incorporation	19 <sup>th</sup> September, 1981
<b>History of last 3 years turnover</b>	<b>Financial Year</b>
1 <sup>st</sup> Previous year turnover	2022-2023: Rs. 2351 Crore
2 <sup>nd</sup> Previous year turnover	2021-2022: Rs. 1768 Crore
3 <sup>rd</sup> Previous year turnover	2020-2021: Rs. 1653 Crore
Country in which the acquired entity has presence	Products of the Company are mainly marketed in the US, India, Canada, Brazil, Europe and 50+ countries in the world. However, Entity has manufacturing facility only in India
Any other significant information (in brief)	None